This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Head and neck cancer	FERM domain containing 4A (FRMD4A)	<p>Patient sample and mouse studies suggest inhibiting FRMD4A could be used to treat head and neck squamous cell carcinoma (HNSCC). In human HNSCC samples, high FRMD4A levels correlated with increased risk of relapse. In a mouse xenograft model of HNSCC, <i>FRMD4A</i> knockdown decreased tumor growth and metastasis compared with normal expression of <i>FRMD4A</i>. Ongoing work includes further elucidating the mechanisms by which FRMD4A controls growth of HNSCC.</p> <p>SciBX 5(22); doi:10.1038/scibx.2012.573 Published online May 31, 2012</p>	Patent application filed; available for licensing	<p>Goldie, S.J. <i>et al. Cancer Res.</i>; published online May 7, 2012; doi:10.1158/0008-5472.CAN-12-0423 Contact: Fiona M. Watt, Cambridge Research Institute, Cancer Research UK, Cambridge, U.K. e-mail: fiona.watt@cancer.org.uk</p>